Advertisement
Advertisement
FDMT
4D Molecular Therapeutics, Inc. Common Stock
10.75
USDSponsored
+0.20
+1.90%
Aug 07, 15:59 UTC -4
Closed
After-Market
10.82
+0.07
+0.70%
FDMT Earnings Reports
Positive Surprise Ratio
FDMT beat 15 of 22 last estimates.
68%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$3.88M
/-$1.04
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
+4206.67%
/+2.97%
4D Molecular Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, FDMT reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -1.03 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 3.16 million, with a --% difference.
Looking ahead to Q3 26, 5 analysts forecast an EPS of -1.04 USD, with revenue projected to reach 3.88 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were 4D Molecular Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, 4D Molecular Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to 4D Molecular Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is 4D Molecular Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for 4D Molecular Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, 4D Molecular Therapeutics, Inc. Common Stock is expected to report EPS of -$1.04 and revenue of $3.88M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement